CVS (CVS): Methodical and efficient, if not idyllic


Continuing with our defensive stock series.... With the markets in a choppy /consolidation mode (or perhaps worse), the drug store chain sector has appeal as a defensive strategy, and CVS Caremark (NYSE: CVS) is a superior performer in the aforementioned sector.

CVS has used acquisition (1,100 Eckerd drugs stores acquired in 2004, 700 Albertson's drugs stores acquired in 2006) and a super-rigorous, systematic store opening plan to create the drug store world's equivalent of a lien, mean, fighting machine: more than 6,200 stores in 43 states.

CVS has the resources, economies of scale, and, arguably, most importantly, the store site selection experience to continue to drive impressive revenue/EPS gains. Further, recent improvements in inventory processes and cost management support the above, and the acquisition of Caremark should add new clients/customers. True, back-store (pharmacy) margins may be pressured by generic competitors, but the front-store (everything else) should make up for it in 2007-2009. CVS's shares closed Tuesday up 39 cents to $40.11.
Time was that grade-school children used to walk to their neighborhood drug store and pick up a needed household item for the parent at home. [In fact, one grade-schooler - - whom the Editor knows very well - - would frequently manage to buy with a portion of his allowance a pack of baseball cards and candy or an ice cream cone during these frequent errands.] In quaint U.S. villages and some small towns, those neighborhood drug stores still exist, few though they may be.

In every other community CVS dominates or is a leading brand, particularly in car-oriented suburban areas. Which is why if you're thinking about starting your own business, you may want to pass on that idea, if it is a line of general-consumer drug stores.

[Note: Technical analysis agnostics stop reading here; all others continue.]

Technically, CVS's chart looks strong. The stock, save only a minor breach this summer, has been above its 50-day moving average for about seven months. The stock did encounter typical 00 resistance at $40 and its p/e at 23 is not low, but assuming it can close consistently above $40 in the weeks ahead, the chart looks poised for further impressive advances.

Stock Analysis: CVS (CVS) is a low-risk stock, and the company's prospects for continued success are bright. Investors seeking a drugs / consumer products defensive play should consider purchasing CVS's shares.
Symbol Lookup
IndexesChangePrice
DJIA-89.2312,801.23
NASDAQ-23.352,903.88
S&P 500-9.311,342.64

Last updated: February 10, 2012: 05:36 PM

Hot Stocks

General Electric

18.875-0.255(-1.33)

Alcoa

10.29-0.35(-3.29)

Apple Inc

493.42+0.25(+0.05)

Google Inc 'A'

605.91-5.55(-0.91)

Bank of America

8.07-0.11(-1.34)

Wal-Mart Stores

61.90-0.06(-0.10)

Exxon Mobil Corp

83.80-1.08(-1.27)

Ford

12.44-0.25(-1.97)

Citigroup

32.925-0.735(-2.18)

IBM

192.42-0.71(-0.37)

Yahoo

16.14+0.14(+0.88)

Starbucks

48.82-0.38(-0.77)

Microsoft

30.495-0.275(-0.89)

Home Depot

45.33+0.06(+0.13)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1328913377008 ms.